GL1X · GenesisL1 explorer

Research workbench

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases

Analyse Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4YTF
Type
protein
Length
285 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v2 / PDB Bank
Contract
0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
Owner
0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
Resolution
1.78
Source
Homo sapiens
Molecule
Tyrosine-protein kinase JAK2
EC
2.7.10.2
UniProt
O60674
Ligands
4HZ
Pockets
4 · best druggability 0.68

Structure

x-ray diffraction · resolution 1.78 · 1 distinct chain · 46% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATyrosine-protein kinase JAK2 (EC 2.7.10.2)protein28546% helix, 18% strandO60674

Ligands and binding sites

  • 4HZ · N~2~-[2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]-N-(2,2,2-trifluoroethyl)-L-alaninamide · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12540.680.84284HZ
23160.570.7735empty
3520.350.7920empty
4810.320.7323empty

Modifications

Observed in the structure: 2 modified (phosphorylation).

Compared structures

  • 4YTF · Discovery of vx-509 (decernotinib): a potent and selective janus kinase (JAK) 3 inhibitor… · the same entry in another collection · chain A against A, TM-score 1.00
  • O60674 · AlphaFold monomer V2.0 prediction for tyrosine-protein kinase JAK2 (O60674) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.